In the last few decades, there has been a growing interest in Bruton's tyrosine kinase (BTK)
and the compounds that target it. BTK is a downstream mediator of the B-cell receptor (BCR) …

The development of Bruton's tyrosine kinase (BTK) inhibitors represents a major
breakthrough in the treatment of chronic lymphocytic leukemia and other B cell …

Autoimmune phenomena are frequently observed in patients with chronic lymphocytic
leukemia (CLL) and are mainly attributable to underlying dysfunctions of the immune …

Purpose Four cases of ibrutinib-related uveitis are presented, which are to the best of our
knowledge the first in the literature. Possible mechanisms of ibrutinib-mediated uveitis are …

Background Advances in molecular biology and genetics have contributed to breakthrough
treatments directed at specific pathways associated with the development of cancer. Small …

A 62-year-old man, normotensive, non-diabetic, was diagnosed with CLL in October 2009,
Rai stage 3, Binet stage B. He was treated initially with chlorambucil monotherapy for 12 …

Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment paradigm of patients
with B-cell lymphomas. In recent years, studies of BTKi have demonstrated superior efficacy …

Introduction: Waldenström's macroglobulinemia (WM), an orphan disease, is a rare low-
grade B-cell lymphoplasmacytic lymphoma with unique clinical features and monoclonal …

The dysregulation of the immune system in Chronic Lymphocytic Leukemia (CLL) often
allows for the development of immune-mediated diseases. Among them, autoimmune …

Introduction Ibrutinib is an oral irreversible inhibitor of Bruton's tyrosine kinase signaling. It is
a well-tolerated agent with some side-effects, the most common of which are atrial …